-
Je něco špatně v tomto záznamu ?
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022
C. Garbe, T. Amaral, K. Peris, A. Hauschild, P. Arenberger, N. Basset-Seguin, L. Bastholt, V. Bataille, V. Del Marmol, B. Dréno, MC. Fargnoli, AM. Forsea, JJ. Grob, C. Hoeller, R. Kaufmann, N. Kelleners-Smeets, A. Lallas, C. Lebbé, B. Lytvynenko,...
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, směrnice pro lékařskou praxi, přehledy
- MeSH
- konsensus MeSH
- lidé MeSH
- melanom * patologie MeSH
- mutace MeSH
- nádory kůže * genetika MeSH
- oximy MeSH
- protokoly protinádorové kombinované chemoterapie MeSH
- protoonkogenní proteiny B-raf genetika MeSH
- staging nádorů MeSH
- systematický přehled jako téma MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- směrnice pro lékařskou praxi MeSH
A unique collaboration of multidisciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recommendations on cutaneous melanoma diagnosis and treatment, based on the systematic literature reviews and the experts' experience. Cutaneous melanomas are excised with one to 2-cm safety margins. Sentinel lymph node dissection shall be performed as a staging procedure in patients with tumor thickness ≥1.0 mm or ≥0.8 mm with additional histological risk factors, although there is as yet no clear survival benefit for this approach. Therapeutic decisions in stage III/IV patients should be primarily made by an interdisciplinary oncology team ("tumor board"). Adjuvant therapies can be proposed in stage III/completely resected stage IV patients and are primarily anti-PD-1, independent of mutational status, or alternatively dabrafenib plus trametinib for BRAF mutant patients. In distant metastases (stage IV), either resected or not, systemic treatment is always indicated. For first-line treatment particularly in BRAF wild-type patients, immunotherapy with PD-1 antibodies alone or in combination with CTLA-4 antibodies shall be considered. In stage IV melanoma with a BRAF-V600 E/K mutation, first-line therapy with BRAF/MEK inhibitors can be offered as an alternative to immunotherapy. In patients with primary resistance to immunotherapy and harboring a BRAF-V600 E/K mutation, this therapy shall be offered as second-line therapy. Systemic therapy in stage III/IV melanoma is a rapidly changing landscape, and it is likely that these recommendations may change in the near future.
1st Department of Dermatology Aristotle University Thessaloniki Greece
Center for Dermatooncology Department of Dermatology Eberhard Karls University Tuebingen Germany
Department of Dermatology Erasme Hospital Université Libre de Bruxelles Brussels Belgium
Department of Dermatology Maastricht University Medical Center Maastricht Netherlands
Department of Dermatology Medical University of Vienna Austria
Department of Dermatology University Hospital Schleswig Holstein Campus Kiel Kiel Germany
Department of Dermatovenereology 3rd Faculty of Medicine Charles University Prague Czech Republic
Department of Oncology Odense University Hospital Odense Denmark
Dermatology Clinic Maggiore Hospital University of Trieste Trieste Italy
Dermatology Department CHU Nantes CIC 1413 CRCINA University Nantes Nantes France
Dermatology Unit University of Modena and Reggio Emilia Modena Italy
Fondazione Policlinico Universitario A Gemelli IRCCS Rome Italy
Institute of Dermatology Università Cattolica Rome Italy
Medical and Surgical Dermatology Service Hospital Universitario Virgen Macarena Sevilla Spain
Melanoma Unit Department of Dermatology Hospital Clinic IDIBAPS Barcelona Spain
Mount Vernon Cancer Centre Northwood United Kingdom
Shupyk National Medical Academy of Postgraduate Education Kiev Ukraine
The University of Manchester Oxford Rd Manchester M13 9PL United Kingdom
Université Paris Cite AP HP Department of Dermatology INSERM U 976 Hôpital Saint Louis Paris France
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22017880
- 003
- CZ-PrNML
- 005
- 20220804134434.0
- 007
- ta
- 008
- 220720s2022 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejca.2022.04.018 $2 doi
- 035 __
- $a (PubMed)35623961
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Garbe, Claus $u Center for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany. Electronic address: claus.garbe@med.uni-tuebingen.de
- 245 10
- $a European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022 / $c C. Garbe, T. Amaral, K. Peris, A. Hauschild, P. Arenberger, N. Basset-Seguin, L. Bastholt, V. Bataille, V. Del Marmol, B. Dréno, MC. Fargnoli, AM. Forsea, JJ. Grob, C. Hoeller, R. Kaufmann, N. Kelleners-Smeets, A. Lallas, C. Lebbé, B. Lytvynenko, J. Malvehy, D. Moreno-Ramirez, P. Nathan, G. Pellacani, P. Saiag, AJ. Stratigos, ACJ. Van Akkooi, R. Vieira, I. Zalaudek, P. Lorigan, European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC)
- 520 9_
- $a A unique collaboration of multidisciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recommendations on cutaneous melanoma diagnosis and treatment, based on the systematic literature reviews and the experts' experience. Cutaneous melanomas are excised with one to 2-cm safety margins. Sentinel lymph node dissection shall be performed as a staging procedure in patients with tumor thickness ≥1.0 mm or ≥0.8 mm with additional histological risk factors, although there is as yet no clear survival benefit for this approach. Therapeutic decisions in stage III/IV patients should be primarily made by an interdisciplinary oncology team ("tumor board"). Adjuvant therapies can be proposed in stage III/completely resected stage IV patients and are primarily anti-PD-1, independent of mutational status, or alternatively dabrafenib plus trametinib for BRAF mutant patients. In distant metastases (stage IV), either resected or not, systemic treatment is always indicated. For first-line treatment particularly in BRAF wild-type patients, immunotherapy with PD-1 antibodies alone or in combination with CTLA-4 antibodies shall be considered. In stage IV melanoma with a BRAF-V600 E/K mutation, first-line therapy with BRAF/MEK inhibitors can be offered as an alternative to immunotherapy. In patients with primary resistance to immunotherapy and harboring a BRAF-V600 E/K mutation, this therapy shall be offered as second-line therapy. Systemic therapy in stage III/IV melanoma is a rapidly changing landscape, and it is likely that these recommendations may change in the near future.
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $7 D000971
- 650 _2
- $a konsensus $7 D032921
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a melanom $x patologie $7 D008545
- 650 _2
- $a mutace $7 D009154
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a oximy $7 D010091
- 650 _2
- $a protoonkogenní proteiny B-raf $x genetika $7 D048493
- 650 12
- $a nádory kůže $x genetika $7 D012878
- 650 _2
- $a systematický přehled jako téma $7 D000078202
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a směrnice pro lékařskou praxi $7 D017065
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Amaral, Teresa $u Center for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany
- 700 1_
- $a Peris, Ketty $u Institute of Dermatology, Università Cattolica, Rome, Italy; Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy
- 700 1_
- $a Hauschild, Axel $u Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Kiel, Germany
- 700 1_
- $a Arenberger, Petr $u Department of Dermatovenereology, Third Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Basset-Seguin, Nicole $u Université Paris Cite, AP-HP, Department of Dermatology INSERM U 976 Hôpital, Saint Louis Paris France
- 700 1_
- $a Bastholt, Lars $u Department of Oncology, Odense University Hospital, Odense, Denmark
- 700 1_
- $a Bataille, Veronique $u Twin Research and Genetic Epidemiology Unit, School of Basic & Medical Biosciences, King's College London, London, SE1 7EH, United Kingdom
- 700 1_
- $a Del Marmol, Veronique $u Department of Dermatology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
- 700 1_
- $a Dréno, Brigitte $u Dermatology Department, CHU Nantes, CIC 1413, CRCINA, University Nantes, Nantes, France
- 700 1_
- $a Fargnoli, Maria C $u Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy
- 700 1_
- $a Forsea, Ana-Maria $u Dermatology Department, Elias University Hospital, Carol Davila University of Medicine and Pharmacy Bucharest, Romania
- 700 1_
- $a Grob, Jean-Jacques $u University Department of Dermatology, Marseille, France
- 700 1_
- $a Hoeller, Christoph $u Department of Dermatology, Medical University of Vienna, Austria
- 700 1_
- $a Kaufmann, Roland $u Department of Dermatology, Venereology and Allergology, Frankfurt University Hospital, Frankfurt, Germany
- 700 1_
- $a Kelleners-Smeets, Nicole $u Department of Dermatology, Maastricht University Medical Center+, Maastricht, Netherlands
- 700 1_
- $a Lallas, Aimilios $u First Department of Dermatology, Aristotle University, Thessaloniki, Greece
- 700 1_
- $a Lebbé, Celeste $u Université Paris Cite, AP-HP, Department of Dermatology INSERM U 976 Hôpital, Saint Louis Paris France
- 700 1_
- $a Lytvynenko, Bodhan $u Shupyk National Medical Academy of Postgraduate Education, Kiev, Ukraine
- 700 1_
- $a Malvehy, Josep $u Melanoma Unit, Department of Dermatology, Hospital Clinic, IDIBAPS, Barcelona, Spain
- 700 1_
- $a Moreno-Ramirez, David $u Medical-&-Surgical Dermatology Service, Hospital Universitario Virgen Macarena, Sevilla, Spain
- 700 1_
- $a Nathan, Paul $u Mount-Vernon Cancer Centre, Northwood United Kingdom
- 700 1_
- $a Pellacani, Giovanni $u Dermatology Unit, University of Modena and Reggio Emilia, Modena, Italy
- 700 1_
- $a Saiag, Philippe $u University Department of Dermatology, Université de Versailles-Saint Quentin en Yvelines, APHP, Boulogne, France
- 700 1_
- $a Stratigos, Alexander J $u First Department of Dermatology, University of Athens School of Medicine, Andreas Sygros Hospital, Athens, Greece
- 700 1_
- $a Van Akkooi, Alexander C J $u Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia
- 700 1_
- $a Vieira, Ricardo $u Department of Dermatology and Venereology, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal
- 700 1_
- $a Zalaudek, Iris $u Dermatology Clinic, Maggiore Hospital, University of Trieste, Trieste, Italy
- 700 1_
- $a Lorigan, Paul $u The University of Manchester, Oxford Rd, Manchester, M13 9PL, United Kingdom
- 710 2_
- $a European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC)
- 773 0_
- $w MED00009626 $t European journal of cancer (Oxford, England : 1990) $x 1879-0852 $g Roč. 170, č. - (2022), s. 256-284
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35623961 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804134428 $b ABA008
- 999 __
- $a ok $b bmc $g 1821801 $s 1169123
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 170 $c - $d 256-284 $e 20220524 $i 1879-0852 $m European journal of cancer $n Eur J Cancer $x MED00009626
- LZP __
- $a Pubmed-20220720
